Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen

Key Points

• Rating change: Wall Street Zen upgraded Cardiol Therapeutics (CRDL) from "sell" to "hold," and the consensus analyst view is a "Hold" with an average target price of $9.00 amid mixed analyst opinions (including HC Wainwright's "buy" with a $9 PT).
• Recent performance: The stock opened at $1.41 with a market cap of about $157.7M and 50/200-day moving averages near $1.06, and the company reported Q1 EPS of ($0.05), beating estimates of ($0.09).
• Business and ownership: Cardiol is a clinical-stage pharma developing CardiolRx, a CBD-based therapy for cardiovascular disease in Phase 2 testing, and institutional investors have been increasing positions (institutional ownership ~12.5%).

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Sunday.

Several other equities analysts have also commented on CRDL. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Cardiol Therapeutics in a research note on Tuesday, February 10th. upgraded shares of Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, February 3rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Cardiol Therapeutics has an average rating of "Hold" and an average target price of $9.00.

Cardiol Therapeutics Stock Performance

Cardiol Therapeutics stock opened at $1.41 on Friday. The firm's 50 day moving average price is $1.06 and its 200-day moving average price is $1.05. The stock has a market cap of $157.67 million, a P/E ratio of -5.04 and a beta of 0.82. Cardiol Therapeutics has a 1 year low of $0.77 and a 1 year high of $1.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.89 and a quick ratio of 3.89.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04. On average, equities analysts predict that Cardiol Therapeutics will post -0.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cardiol Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CRDL. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Cardiol Therapeutics in the fourth quarter valued at approximately $31,000. Simplex Trading LLC raised its holdings in shares of Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company's stock worth $31,000 after purchasing an additional 15,842 shares during the period. AdvisorShares Investments LLC lifted its stake in shares of Cardiol Therapeutics by 7.3% in the 4th quarter. AdvisorShares Investments LLC now owns 597,977 shares of the company's stock valued at $570,000 after purchasing an additional 40,589 shares in the last quarter. Integrity Alliance LLC. purchased a new stake in shares of Cardiol Therapeutics during the 4th quarter worth about $416,000. Finally, Tejara Capital Ltd grew its holdings in shares of Cardiol Therapeutics by 95.1% during the 4th quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company's stock worth $4,893,000 after purchasing an additional 2,500,000 shares during the period. Institutional investors and hedge funds own 12.49% of the company's stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.